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Abstract: Several factors may be responsible
for the high prevalence of atherosclerosis in
diabetes mellitus, including alterations in
reverse cholesterol transport. In the present
study,
the
activity
of
plasma
lecithin:cholesterol acyltransferase (LCAT) and
the cholesteryl ester transfer rate, and
concentrations of lipids and lipoproteins were
measured in 11 patients with insulindependent diabetes mellitus (type 1), 42
patients with noninsulin-dependent diabetes
mellitus (type 2) and compared with those in
age-matched control groups (Control I, n =
14; and Control II, n = 29, respectively). No
statistically significant differences were
observed in plasma total cholesterol,
triglyceride, ester cholesterol or very low
density
lipoprotein
(VLDL)-cholesterol
concentrations between the diabetic and
control groups. High density lipoprotein
(HDL)- and HDL2-cholesterol levels were
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Introduction
Atherosclerosis is an important complication of
diabetes mellitus (1). Why diabetes mellitus should be
associated with an increased premature atherosclerosis
risk is not clear, but it has been partly attributed to
disturbances in reverse cholesterol transport (2). This is
a multi-step process and includes the uptake of free
cholesterol (FC) by high density lipoprotein (HDL) from
cell membranes, the esterification of FC at the HDL
surface by lecithin:cholesterol acyl transferase (LCAT),
which is mainly activated by apolipoprotein (apo) A-I, and
the transfer of esterified cholesterol (CE) to apo Bcontaining lipoproteins (low density lipoprotein, LDL; very
low density lipoprotein, VLDL), which is catalyzed by the
cholesteryl ester transfer protein (CETP). The rate of CE
mass transfer depends not only on levels of CETP but also
on the concentration and composition of the plasma
lipoproteins involved in the transfer process (3).

significantly lower in the diabetic patients.
Plasma free cholesterol and low density
lipoprotein (LDL)-cholesterol concentrations
were higher in the type 2 diabetics than in the
control subjects. LCAT activity was
significantly lower in both groups of diabetic
patients than in the control groups. The mass
of cholesteryl ester transferred from HDL to
VLDL + LDL was significantly greater in the
diabetic groups than in the controls. In
conclusion, the decrease in LCAT activity and
the increase in cholesteryl ester transfer
observed with both type 1 and type 2
diabetics could affect the reverse cholesterol
transport of HDL and contribute to the
development of atherosclerosis in diabetes.
Key Words: Diabetes, Lecithin:cholesterol
acyltransferase, Cholesteryl ester transfer,
Reverse cholesterol transport

HDL plays a central role in reverse cholesterol
transport because it not only promotes the efflux of
cholesterol from peripheral tissues but is also the major
site for the esterification of cholesterol by LCAT. LCAT
activity modulates cholesterol transfer from lipoproteins
and cell membranes to HDL. Therefore, decreased activity
of LCAT promotes the accumulation of FC at cell
membranes, and of remnant lipoprotein in plasma, both
factors being strongly related to atherosclerosis (4,5).
Modifications in the cholesteryl ester transfer (CET) are
potentially atherogenic if the compositional changes
adversely affect the function of lipoproteins. The question
of whether CET is a beneficial or deleterious process
remains unresolved. If CET were inhibited because the
efflux of cholesterol from arterial wall tissues were
retarded, it could have potentially atherogenic
consequences (6,7). On the other hand, it seems likely
that when CET is accelerated, more atherogenic
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cholesteryl ester-enriched apo B-containing lipoproteins
will be formed (8).
There has been considerable controversy concerning
the process of the CET rate in diabetes mellitus. The
objective of the present study was to measure cholesteryl
ester transfer from HDL to apo B-containing lipoproteins
in insulin-dependent (type 1) and noninsulin-dependent
(type 2) diabetics, as compared to normal controls
matched for age.

Materials and Methods
1. Subjects: Eleven subjects (six female, five male,
aged 29 ± 11 years; mean ± SD) with insulin-dependent
diabetes mellitus (IDDM) (duration 10 ± 8 years; mean ±
SD) and 42 subjects (21 female, 21 male, aged 58 ± 11
years; mean ± SD) with noninsulin-dependent diabetes
mellitus (NIDDM) (duration 8 ± 6 years; mean ± SD)
were studied as outpatients. The classification of these
patients was based on clinical criteria (9). At the time of
the study all noninsulin-dependent diabetic patients were
being treated with an oral sulfonylurea agent and diet.
The insulin-dependent diabetic patients were in a stable
metabolic condition (none had a history of ketoacidosis in
the 3 months prior to the study) by the use of multiple
daily insulin injections. The last administration of insulin
was 12 h preceding the blood sampling. Age-matched
control groups were formed for both IDDM and NIDDM
groups [Control I (n = 14, six female and eight male,
aged 27 ± 7 years) and Control II (n = 29, 11 female and
18 male, aged 51 ± 9 years), respectively]. All
participants were non-smokers; none were receiving
medications affecting the lipid metabolism, or had hepatic
or renal disease. All patients and control subjects were
informed volunteers.
2. Methods:
Chemicals: 5,5'-dithiobis(2-nitrobenzoic acid),
polyvinyl sulfate-potassium salt, magnesium chloride and
dextran sulfate (MW: 15,000) were purchased from
Sigma. Dextran sulfate-sodium salt (MW: 500,000) and
polyethylene glycol 350 monomethyl ether were obtained
from Pharmacia Fine Chemicals and Fluka, respectively.
Sample preparation: Blood samples were drawn into
tubes containing EDTA after fasting overnight. Plasma
was separated by low-speed centrifugation (900 x g, for
10 min) and the parameters described below were
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analyzed immediately. Glucose was measured by the
glucose oxidase method. Glycosylated hemoglobin was
measured in fasting blood using a chromatographic kit
(Boehringer, Germany). Plasma total cholesterol (TC)
(Boehringer, Germany) and triglyceride (TG) (Chematil,
Italy) were determined by enzymatic methods. The
plasma HDL-cholesterol level was determined after
precipitation of apo B-containing lipoproteins with
dextran sulfate-magnesium chloride (10). HDL2 was
precipitated in the clear supernatant containing the HDL
by using low-molecular weight dextran sulfate (MW:
15,000). After the precipitation of HDL2, the cholesterol
level was measured in the HDL3 supernatant to determine
the HDL3-cholesterol level. The concentration of HDL2cholesterol was estimated as the difference between the
HDL-cholesterol and HDL3-cholesterol (11). Plasma FC
was measured by an enzymatic kit (Boehringer,
Germany), and the concentration of cholesteryl ester was
calculated by subtracting FC from TC. The LDLcholesterol concentration was determined after
precipitating LDL with polyvinyl sulfate. The
concentration of LDL-cholesterol was estimated as the
difference between the total and the supernatant
cholesterol values (12). Cholesterol and TG
measurements were performed on a Shimadzu 1202
spectrophotometer (Japan).
LCAT activity measurement: Plasma LCAT activity was
determined as a function of the decrease in FC, which is
esterified during incubation at 37 ºC, as described by Hitz
et al. (13). LCAT activity was expressed as the reduction
-1 -1
in FC (µmol/L h ) in the assay mixture.
CE transfer in plasma: The CE mass transfer, which
measures the net transfer of preformed CE from HDL to
the apo B-containing lipoproteins in intact plasma, was
measured as described by Bagdade et al., in which freshly
drawn plasma was incubated at 37 ºC in a shaking water
bath in the presence of 5,5’-dithiobis (2-nitro-benzoic
acid) (DTNB) (final concentration of DTNB was 1.5
mmol/L) to inhibit LCAT (14). Aliquot samples of plasma
were removed after 2 and 4 h of incubation and chilled
on ice, and VLDL + LDL were precipitated from plasma by
using a combined dextran sulfate-magnesium chloride
reagent (10 g dextran sulfate and 1.5 mol magnesium
chloride/L) so that the final concentrations of the
precipitant were 0.909 g/L dextran sulfate and 0.136
mol/L magnesium chloride. At each sampling interval the
transfer of CE from HDL to apo B-containing lipoproteins
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was determined by measuring the decrease in the mass of
CE (mg/L) present in the supernatant containing HDL.
The LCAT activity and CE transfer assays were performed
in duplicate. The within-day coefficients of variation were
5.5% and 7.0% for LCAT and CE transfer rate,
respectively.
Statistical analysis: Quantitative variables are
expressed as mean ± SD. The data obtained for diabetics
and controls were compared by Student’s t-test.
Pearson's correlation coefficients were used to test for
relationships between variables. A p value of less than
0.05 was considered significant.

Results
The clinical features of the IDDM, NIDDM and control
subjects are shown in Table 1. As expected, both fasting
glucose and glycated hemoglobin (Hb A1c) levels were
significantly increased in the diabetics.
Table 2 shows plasma lipid and lipoprotein
concentrations in diabetic patients and healthy individuals.
The plasma TC level of the diabetic patients was not
statistically different from those of the control subjects.
The plasma TG concentration was slightly higher in the
diabetic groups compared with the respective control
groups, but the differences were not statistically
significant. Plasma HDL-cholesterol and HDL2-cholesterol
were significantly lower in IDDM patients compared with
their control subjects. Plasma levels of FC and LDLcholesterol were significantly higher (p < 0.001 and p <
0.05, respectively), while plasma HDL-cholesterol was
significantly decreased (p < 0.01) in NIDDM patients
compared to Control II subjects. This decrease occurred in

Table 1.

both HDL subfractions. Plasma LCAT activity was reduced
in IDDM and NIDDM patients (p < 0.001 for both),
compared with their controls (Table 2).
CET responses of NIDDM subjects differed
significantly from those of the non-diabetic controls. In
the Control-II group, 21.6 ± 6.8 and 64.3 ± 20.6 mg of
CE was transferred to VLDL and LDL at the 2 h and 4 h
intervals, respectively. In the NIDDM group, however, the
CE transfer rates under the same conditions were 27.0 ±
8.9 and 80.9 ± 20.1 mg of CE transferred to VLDL and
LDL, significantly greater at both sampling intervals (p <
0.05 and p < 0.01, respectively) than that found in the
Control-II group (Figure 1). CE transfer to VLDL + LDL
was also altered in the IDDM patients. In the Control-I
group, 19.8 ± 7.7 and 50.2 ± 10.5 mg of CE was
transferred to VLDL + LDL at the 2 h and 4 h intervals,
respectively. In the IDDM group, the CE transfer rates
were 21.6 ± 10.3 and 68.9 ± 30.0 mg/L. The net mass
of CE transferred from HDL to VLDL + LDL was
significantly greater than that in the Control-I group at 4
h (p < 0.05). The CE mass transferred at 2 h in the IDDM
group was slightly higher than that in the Control-I group
but the difference was not statistically significant (p <
0.05) (Figure 2).
Correlation analyses: The CE mass transferred at 4 h
was correlated significantly with age (r = 0.359, p <
0.05) and HDL2-C levels (r = - 0.320, p < 0.05) in
control subjects. In diabetic subjects, both plasma FC and
VLDL-C were positively correlated with CE transfer rate
at 4 h (r = 0.338, p < 0.05; r = 0.337, p < 0.05,
respectively). LCAT activity was found to negatively
correlate with plasma glucose concentration in diabetic
patients (r = -0.310, p < 0.05).

Characteristics of patients and control subjects.

Parameter

IDDM patients
(n = 11)

Control I
(n = 14)

p value

NIDDM patients

Control II
(n = 42)

p value
(n = 29)

Age (years)

28.0 ± 10.9

26.8 ± 7.1

-

58.0 ± 10.7

50.8 ± 8.9

-

6/5

6/8

-

21/21

11/18

-

20.9 ± 1.8

23.0 ± 3.0

<0.05

26.4 ± 4.0

25.9 ± 2.6

NS

Gender (F/M)
2

BMI (kg/m )
Glucose (mg/dL)

233 ± 88

83 ± 5

<0.001

193 ± 64

87 ± 8

<0.001

HbA1c, %

10.6 ± 3.6

5.2 ± 0.5

<0.001

8.7 ± 2.2

5.0 ± 0.6

<0.001

BMI: Body mass index, HbA1c: Hemoglobin A1c, NS: Non-significant
Data are expressed as mean ± S.D.
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Table 2.

Plasma lipids in diabetics and control subjects.

Parameter

IDDM patients

Control I

p value

NIDDM patients

Control II

p value

TC (mg/dL)

170 ± 31

178 ± 33

NS

196 ± 35

186 ± 34

NS

FC (mg/dL)

43.6 ± 10.0

49.0 ± 14.4

NS

55.6 ± 12.7

47.1 ± 7.6

<0.001

CE (mg/dL)

126.7 ± 21.9

128.7 ± 20.9

NS

140.4 ± 25.3

138.7 ± 28.3

NS

FC/CE

0.344 ± 0.04

0.377 ± 0.07

NS

0.396 ± 0.07

0.347 ± 0.05

<0.001

HDL-C (mg/dL)

43.0 ± 7.7

50.6 ± 10.7

<0.05

44.3 ± 9.5

50.1 ± 9.9

< 0.01

HDL2-C (mg/dL)

15.4 ± 3.3

19.8 ± 3.5

<0.01

16.8 ± 3.9

18.9 ± 3.3

<0.01

HDL3-C (mg/dL)

27.6 ± 6.2

30.9 ± 8.1

NS

27.5 ± 6.4

31.2 ± 7.5

<0.05

LDL-C (mg/dL)

93 ± 27

103 ± 28

NS

117 ± 27

104 ± 29

<0.05

VLDL-C (mg/dL)

28 ± 10

24 ± 10

NS

34 ± 23

31 ± 14

NS

TG (mg/dL)

142 ± 48

121 ± 52

NS

170 ± 114

153 ± 69

NS

28.5 ± 14.8

59.5 ± 25.4

< 0.001

28.4 ± 14.9

46.8 ± 21.5

<0.001

LCAT (µmol/L/h)

Data are expressed as mean ± S.D.
TC: Total cholesterol, FC: Free cholesterol, CE: Cholesterol ester, HDL-, LDL-, VLDL-C: High, low, very low density lipoprotein-cholesterol, TG:
Triglycerides, LCAT: Lecithin: cholesterol acyltransferase
NS: Non-significant

80
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80
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0

IDDM patients
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40
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0
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Figure 1.

2
Hours

4

Mass of cholesterol ester (CE) transferred in plasma from
HDL to VLDL + LDL in noninsulin dependent diabetes
mellitus (NIDDM) patients and control subjects during a 4h incubation at 37 ºC.

Discussion
Reverse cholesterol transport is a multi-step process
including lipoproteins, enzymes and transport proteins.
HDL plays a central role in this process. Free cholesterol
taken up by HDL from peripheral tissue is esterified by
LCAT. Thus, LCAT contributes to maintaining a
concentration gradient of free cholesterol between
peripheral tissues and HDL, and promotes cholesterol
movement from tissue to HDL.
98

Control-I

Control-II
CE transferred (mg/L)

CE transferred (mg/L)

100

0
Figure 2.

2
Hours

4

Mass of cholesterol ester (CE) transferred in plasma from
HDL to VLDL + LDL in insulin dependent diabetes mellitus
(IDDM) patients and control subjects during a 4-h
incubation at 37 ºC.

CETP mediates the transfer of CE and triglyceride
between HDL and apolipoprotein B-containing
lipoproteins. Inhibition of the transport may be
atherogenic because the efflux of cholesterol from tissues
would be retarded. On the other hand, promotion of this
process is probably proatherogenic because CETP may
lead to enrichment of apo B-containing lipoproteins with
CE (15). An increased rate of CE transport has been
postulated to be responsible for the higher risk of
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atherosclerosis by various investigators (16-19). CETP
activity has been reported to be normal or lower in
diabetic patients (6,20). However, studies reporting the
accelerated transfer of CE from HDL to apolipoprotein Bcontaining lipoproteins seem to be more common
(14,15,21-25). The higher CE transfer rate observed in
both types of diabetic patients in the present study is in
agreement with the latter studies. This functional
alteration was attributed to abnormalities in the
concentration and composition (apolipoprotein E, FC and
phospholipid, free fatty acid) of apo B-containing
lipoproteins (26-30). Among other possible explanations
are glycation of lipoproteins involved in CE transfer (31)
and increased CETP mass at elevated plasma glucose
concentrations (21,32). Several investigators have
reported that high CE transfer protein activity is related
to low plasma HDL-C levels in various conditions (16, 3335) and may lead to the development of atherosclerosis.
In the present study, we have demonstrated that
cholesterol levels in HDL fraction and HDL2 and HDL3
subfractions were significantly lower in diabetic groups
than in their respective controls (p > 0.05 in HDL3
subfraction between type 1 diabetics and Control I).
Although a decrement in HDL2-C levels has been
postulated to be responsible for the lower risk of
coronary heart disease (CHD), it has been recently
suggested that low levels of HDL3 may also be associated
with higher CHD risk (36).

described increased activity of LCAT in diabetics (41),
whereas Fielding et al. found decreased activity (42). On
the other hand, Misra and Schernthaner reported that the
LCAT activities of diabetic patients were similar to those
found in controls (43,44). Weight and coworkers
reported that although LCAT activity did not differ
between poorly controlled type 1 diabetic patients and
control subjects, a significant increase was observed in
plasma LCAT activity with an improvement in metabolic
control (45). In this study, we have demonstrated that
LCAT activity was lower in both IDDM and NIDDM
patients than in the control subjects. The discrepancies
among the studies suggest that, in diabetes, HDL particles
may be submitted to complex alterations, including
compositional modifications. Results on compositional
alterations in diabetic HDL are conflicting (14,40,46).
Alterations in HDL lipid composition could have effects on
LCAT activity, because it has been well established that
the chemical and physical properties of the particle are
critical in determining the enzymatic reaction rate (40).

Alterations in the reverse cholesterol transport have
been described in a number of conditions carrying a high
risk of atherosclerosis, such as diabetes. Chronic
hyperglycemia in diabetic patients leads to nonenzymatic
glycation of proteins including apo A-I (37). This
modification of apo A-I results in a decrease of LCAT
activity (38,39). It has been shown by Fournier et al. that
LCAT reactivity decreased in both native diabetic HDL and
in vitro glycated HDL (40).
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